Our experience with ball valve replacement of the mitral valve during the past decade is presented in terms that allow comparison with other techniques. The use ofsuch prostheses is characterized by ease of implantation, with an overall operative mortality of II per cent for isolated mitral replacement and 13 per cent for multiple valve replacement. The operative mortality for isolated mitral valve replacement during I969 and thus far in 1970 has been nil. The late mortality was 13 per cent for isolated mitral replacement and 20 per cent for multiple valve replacement. Forty-three per cent of the total late deaths were clearly unrelated to the prosthetic device itself.
The overall incidence of late infection and leak is less than I per cent and the immediate haemodynamic benefit is not altered by loss of structural integrity of the prosthesis.
The most serious problem after mitral valve replacement with the ball valve prosthesis is that of thromboembolic complications. While thrombotic stenosis of the prosthesis is a rarity, embolic episodes, usually cerebral in type, have been noted in 63 per cent of the patients surviving mitral valve replacement with the earliest model ball valve from August I960 to February I966. Improvements in valve design have resulted in a remarkable decrease in this incidence as examined by actuarial techniques and taking into account the duration offollow-up. The extension of the cloth sewing margins to the orifice of the valve while maintaining a metallic orifice and metallic cage (Model 6120) resulted in a drop of the thromboembolic rate to 17 per cent from April I965 to April 1969. The development of the totally cloth-covered prosthesis hasfurther improved these results, with only one thromboembolic complication after isolated mitral valve replacement with the Model 6310 valve in a series of 66 consecutive patients. In clinicalpractice this has resulted in the avoidance of the use of anticoagulant therapy in patients in whomfor a variety of reasons this carries an increased hazard. With further follow-up it may be possible to discontinue the routine use of anticoagulants.
The past decade has seen considerable progress in the surgical management of mitral valve disease. The selection of patients for operation, the application of a replacement or reparative procedure, and the physiological basis for sound postoperative care are well established. However, the method of choice for replacement of the mitral valve, whether by prostheses of synthetic material, prostheses of diverse biological material, or autogenous tissue, is still under consideration.
Our own experience has been overwhelmingly with the ball valve prostheses (Starr and Edwards, I96I 
Clinical Material
Our experience with open heart surgery of the mitral valve is shown in Fig. I June 1970. instances in which the ruptures were multiple a replacement was performed.
The importance of correction of associated valve disease was recognized early in our experience (Starr et al., i964a, b) . The first combined mitral and aortic replacement was performed in July I962 and the first triple valve replacement in February I963. While preoperative haemodynamic and contrast studies were performed in most patients, the median stemal splitting approach was adopted to allow a thorough reassessment of all the valvular pathology so that total correction could be performed. The management of tricuspid valve disease is as previously reported (Starr, Herr, and Wood, I966a; Starr, I969) . While tricuspid commissurotomy is applicable to some patients, tricuspid valve replacement is performed in most patients with severe organic tricuspid valve disease. The tricuspid valve is also replaced in patients with faradvanced and irreversible functional tricuspid regurgitation. This condition is due to prolonged right ventricular hypertrophy and dilatation and results in a relative subvalvular shortening associated with varying degrees of annular dilatation. In our experience annuloplasty has not been effective in overcoming this complex disproportion between valve and ventricle over the long term. During the past few years coronary arteriography has been used with increasing frequency in patients over 40 years of age. Patients with associated coronary lesions amenable to saphenous vein bypass procedures have been accepted for combined operations. Patients with advanced and irreparable coronary artery disease are excluded for operation.
Prostheses
The various models of the mitral ball valve prosthesis used in man from August I960 to the present time are shown in Fig. 2 the atrial side and diminish the incidence of perivalvular leak. The struts were thinned, the orifice to ball ratio increased, the stroke decreased, and the clearance between the silicone rubber ball and the struts was decreased to further reduce the bulk of the cage. This prosthesis provided superior hydraulic function to the previous model of the same external dimensions (Fig. 2C) . In April i967, after two years of experience in the animal laboratory, the first totally clothcovered prosthesis was used in man for mitral replacement in the form of the Model 6300 series (Fig. 2D ). This prototype valve contained a hollow metallic ball of Stellite with a specific gravity of ogoo in a cage of Stellite 21 covered by Dacron or more commonly Teflon cloth, or both. Fig. 3 shows a Model 6300 in place nine months after implantation in a patient killed in an automobile accident. There is complete covering of the valve with a glistening transparent autogenous tissue.
In order to protect the cloth in the orifice from the shear forces produced by ball closure the orifice to ball ratio was reduced considerably, resulting in some decrease in hydraulic performance as compared with the Model 6I20. This was confirmed by postoperative cardiac catheterization and led, in December I968, to the clinical use of the current cloth-covered 6310 series (Fig. 4) . This prosthesis has a sewing ring of Teflon and polypropylene, the former for lubricity and the latter for structural integrity. The struts are covered with two layers of cloth: an inner Teflon layer to form a suitable bed for an outer layer of polypropylene. The orifice to ball ratio was increased to produce hydraulic function comparable to the Model 6120. Protection of the cloth in the orifice is provided by small metallic studs spaced between Teflon or currently polypropylene fibres. Fig. 5 shows a composite orifice valve (Model 63I0) removed nine months after implantation because of a large perivalvular leak. Neointima covers the entire valve except for the small metallic studs. There is no thrombus material at the junction of the metallic studs and cloth.
With the introduction of the composite seat, tear of the orifice cloth has not been seen. Partial thickness tear of the strut cloth with the earlier model totally cloth-covered valve (Model 6300) has been observed in one specimen in our series but was of no functional consequence. A strut cloth tear has not been seen with the current strut covering of double layer Teflon or inner layer Teflon and outer layer polypropylene. Much has been learned about the mechanism and correction of strut cloth tear from extracorporeal accelerated fatigue tests. These show that the first step in the process is a spreading apart of the longitudinal fibres on the inner aspect of the strut, followed by wearing down of the transverse fibres due to contact with the ball. Measures taken to avoid separation of longitudinal fibres and to lessen lateral excursion of the ball have greatly diminished the rate at which cloth tear may occur. In addition, polypropylene is superior to Teflon or Dacron in this respect. It is not likely, there-FI G. 3 Model 6300 mitral prosthesis nine months after implantation. Note absence of thrombus material and the glistening neointima covering the cloth surfaces.
fore, that strut cloth tear will be a significant problem after mitral valve replacement with totally cloth-covered valves. Careful and continued observation, however, will be necessary to confirm this, since extracorporeal fatigue studies cannot be used as an accurate projection of in vivo future performance. 
Results
The operative mortality in this series consists of all deaths occurring during the first month after implantation, or occurring later but due to a complication starting in the first month (Table i) . There has been a sharp reduction 
o03 per cent for the 6I20, 2 per cent for the 6300, and i per cent for the 63I0. The apparent lack of improvement with the completely cloth-covered valves compared with the extended cloth valve (Model 6I20) is not surprising, since thrombus formation would not necessarily be suppressed until healing occurred. While the slopes of the actuarial curves provide useful information with regard to the risk of embolism related to time, the number of patient months of follow-up with each type of valve is not shown. Table 4 presents this information in terms of the incidence of thromboembolic complications per i,ooo patient months of follow-up. The improvement provided by the 6I20 prosthesis is striking. The excellent results obtained with the 63I0 prosthesis are related to an experience only one- 
